Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_assertion type Assertion NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_head.
- NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_assertion description "[Although the most widely studied genes are the cell-cycle inhibitors p15INK4b and p16INK4a (specially in AML and ALL), the list of methylation-repressed genes in these neoplasms is expanding very rapidly, including MGMT, RARB2, CRBP1, SOCS-1, CDH1, DAPK1, and others.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_provenance.
- NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_assertion evidence source_evidence_literature NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_provenance.
- NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_assertion SIO_000772 14585279 NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_provenance.
- NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_assertion wasDerivedFrom befree-2016 NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_provenance.
- NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_assertion wasGeneratedBy ECO_0000203 NP418691.RAYkdGxY29HUefbsW7wb8RVL4ixL8vFgrzXfNVKpABBNE130_provenance.